查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
美国幽门螺杆菌非侵入性测试市场预测至2028年 - 按测试类型、测试方法和终端用户分類的COVID-19影响和国家分析
市场调查报告书
商品编码
1296776

美国幽门螺杆菌非侵入性测试市场预测至2028年 - 按测试类型、测试方法和终端用户分類的COVID-19影响和国家分析

US Helicobacter Pylori Non-Invasive Testing Market Forecast to 2028 - Country Analysis By Test Type, Test Method, and End User
出版日期: | 出版商: The Insight Partners | 英文 112 Pages | 订单完成后即时交付

价格

美国幽门螺杆菌无创检测市场规模预计将从2022年的2.2376亿美元增长到2028年的3.0279亿美元；估计从2023年到2028年将录得5.3%的复合增长率。美国幽门螺杆菌无创检测市场的增长归因于幽门螺杆菌细菌感染率的增加和幽门螺杆菌无创检测市场开发活动的上升。然而，幽门螺杆菌的无症状性阻碍了美国幽门螺杆菌无创检测市场的增长。

幽门螺杆菌是一种引起胃部感染、消化性溃疡和胃炎的细菌。长期的细菌感染在某些情况下可能会导致胃癌。幽门螺杆菌感染在美国的西班牙裔和黑人人口中更常见，这可以归功于社会经济因素，如低收入和识字率，家庭拥挤和大规模移民。因此，幽门螺杆菌感染患病率的增加推动了美国幽门螺杆菌无创检测市场。

幽门螺杆菌感染通常发生在有长期临床症状的儿童身上，如胃炎、消化性溃疡病和胃癌。根据发表在《自然》杂志上的一篇文章，幽门螺杆菌存在于约36%的美国人口中，对胃癌和消化性溃疡病构成重大风险。世界卫生组织（WHO）已经承认幽门螺杆菌是导致胃癌的致癌物，在美国，胃癌是第三大最常见的胃肠道癌症。根据美国癌症协会的数据，2023年将有近26,500个新的胃癌病例和约11,130人因这种癌症类型而死亡。因此，不断增长的癌症病例增加了美国幽门螺旋杆菌无创检测市场的增长。

此外，日益增长的老年群体对胃部疾病的易感性将大大增加幽门螺杆菌感染的风险。衰老导致胃黏膜变薄，从而使细菌通过保护性黏膜，从而增加老年人的疾病发病率。鉴于老年人口基数的不断增加，《华盛顿邮报》估计，到2040年美国将有近8080万老年公民。因此，老年人口的增长促进了美国幽门螺杆菌无创检测市场的增长。

根据美国国家卫生研究院的一份报告，2020年美国10岁以下儿童的幽门螺杆菌发病率为5%。此外，美国卫生与公众服务部报告说，30-40%的美国人感染了幽门螺杆菌。此外，社会经济因素，如低收入、缺乏教育、家庭拥挤和移民，也是导致美国西班牙裔和黑人人口感染幽门螺杆菌的原因。这些统计数据决定了美国对幽门螺杆菌无创诊断的需求增加，从而推动了美国幽门螺杆菌无创检测市场的增长。

测试类型的洞察力

根据测试类型，美国幽门螺旋杆菌无创检测市场被分为尿素呼吸、粪便抗原和血清学。2022年，尿素呼吸部分占据了美国幽门螺杆菌无创检测市场的最大份额。此外，在未来几年内，该部分预计将以最快的速度增长。尿素呼吸试验（UBT）是检测幽门螺杆菌感染的基本无创方法之一。该测试包括根据幽门螺杆菌产生尿素酶的能力来检测，尿素酶会将口服的尿素水解成二氧化碳和氨。这些气体扩散到血液中，然后由肺部排泄出来。UBTs是可靠的、低负担的测试，在成人和儿童中得到验证。因此，这些有助于美国幽门螺旋杆菌无创检测市场规模的增长。

根据英国癌症研究中心，慢性细菌感染会导致长期的胃部炎症，也被称为严重的慢性萎缩性胃炎或SCAG；长时间的胃溃疡甚至会导致癌症。根据世界卫生组织（WHO）的数据，癌症是全世界死亡的一个重要原因；2021年世界上大约有190万新的癌症病例。结直肠癌是一种常见的类型，2022年有146,589个新病例记录。这种类型的癌症在中年和老年人口中更为流行。它很少发生在40岁以下有遗传易感性或易感条件的人中。通过适当的测试早期发现幽门螺杆菌对预防结肠癌是必要的。早期诊断对于降低与癌症有关的死亡率是至关重要的。因此，不断上升的细菌感染病例需要进行尿素呼吸试验，这有助于美国幽门螺杆菌无创检测市场的增长。

2020年2月，Gulf Coast Scientific公司的Pylo Plus UBT系统获得了美国食品和药物管理局（FDA）的批准，这是一种用于检测幽门螺杆菌感染的13C UBT。此外，美国幽门螺杆菌无创检测市场的主要参与者形成联盟，推出新产品并扩大其影响力。例如，在2021年，Meridian Bio签署了一项协议，以2000万美元的价格从大冢制药公司收购BreahTrek。这种合作导致了UBT领域新产品的推出，并在预测期内促进了美国幽门螺旋杆菌无创检测市场的整体增长。

目录

第一章：简介

  • 本研究的范围
  • Insight Partners的研究报告指导
  • 市场细分
    • 美国幽门螺杆菌（H. pylori）非侵入性测试市场 - 按测试类型划分
    • 美国幽门螺杆菌（H. pylori）非侵入性测试市场 - 按测试方法划分
    • 美国幽门螺杆菌（H. pylori）非侵入性检测市场 - 按终端用户分类

第二章：美国幽门螺旋杆菌（H. pylori）无创检测市场的主要结论

第三章：研究方法

  • 覆盖面
  • 二级研究
  • 初级研究

第四章：美国幽门螺旋杆菌（H. pylori）无创检测市场 - 市场格局

  • 幽门螺旋杆菌（H. pylori）无创检测市场 - 市场格局概述
  • PEST分析
    • 美国PEST分析
  • 专家意见
  • 美国幽门螺杆菌（H. pylori）无创检测市场，按检测类型划分 - 2022年数量（百万）。

第五章：幽门螺杆菌（H.pylori）非侵入性检测市场 - 主要行业动态

  • 主要的市场驱动因素
    • 幽门螺杆菌感染的发病率不断上升
    • 幽门螺杆菌非侵入性检测的市场开发活动不断增加
  • 主要的市场限制因素
    • 幽门螺杆菌的无症状性
  • 主要的市场机会
    • 越来越多地使用基于家庭的护理点设备
  • 未来趋势
    • 幽门螺杆菌非侵入性测试的技术进步和创新
  • 影响分析

第六章：美国幽门螺杆菌（H. pylori）非侵入式检测市场分析

  • 美国幽门螺杆菌（H. pylori）无创检测市场收入预测和分析
  • 主要参与者的市场定位

第7章 ：美国幽门螺杆菌（H. pylori）无创检测市场分析 - 按检测类型划分

  • 概述
  • 尿素呼吸
  • 粪便抗原
  • 血清学

第八章：美国幽门螺杆菌（H. pylori）非侵入性检测市场分析 - 按检测方法分类

  • 概述
  • 以实验室为基础
  • 护理点

第九章：美国幽门螺杆菌（H. pylori）非侵入性检测市场分析 - 按终端用户分类

  • 概述
  • 医院
  • 参考实验室
  • 其他

第十章：美国幽门螺杆菌（H. pylori）非侵入性检测市场

  • 美国

第十一章 ：美国幽门螺杆菌（H. pylori）非侵入性检测市场 - 行业格局

  • 概述
  • 幽门螺杆菌非侵入性检测市场的增长策略
  • 无机增长战略
    • 概述
  • 有机增长策略
    • 综述

第十二章 ：公司简介

  • Bioneer Corp
  • Meridian Bioscience Inc
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc
  • Bio-Rad Laboratories Inc
  • Coris BioConcept SPRL
  • DiaSorin SpA
  • Sekisui Diagnostics LLC
  • CerTest Biotec SL
  • QuidelOrtho Corporation

第十三章 ：附录

  • 关于洞察力合作伙伴
  • 术语表
Product Code: TIPRE00029913

The US Helicobacter Pylori Non-Invasive Testing Market size is expected to grow from US$ 223.76 million in 2022 to US$ 302.79 million by 2028; it is estimated to record a CAGR of 5.3% from 2023 to 2028. The US Helicobacter Pylori non-invasive testing market growth is attributed to the increasing prevalence of H. pylori bacterial infection and rising market development activities in H. pylori non-invasive test. However, asymptomatic nature of H. pylori is hampering the growth of the US Helicobacter Pylori Non-Invasive Testing market.

H. pylori is a bacterium causing stomach infection, peptic ulcer, and gastritis. The prolonged bacterial infection may lead to stomach cancer in some cases. The H. pylori infection is more common in the US Hispanic and black populations, which can be credited to socioeconomic factors such as low income and literacy, household crowding, and large-scale immigration. Thus, increase in prevalence of H. pylori infection fuel the US Helicobacter pylori non-invasive testing market.

The H. pylori infection usually occurs in children with long-standing clinical symptoms such as gastritis, peptic ulcer disease, and stomach cancer. According to an article published in the Nature Journal, H. pylori is present in ~36% of the US population, posing a significant risk for gastric cancer and peptic ulcer disease. The World Health Organization (WHO) has recognized H. pylori as a carcinogen that leads to gastric cancer and in the US, gastric cancer is the third most common gastrointestinal cancer. According to the American Cancer Society, nearly 26,500 new cases of stomach cancer and ~11,130 deaths will occur due to this cancer type in 2023. Thus, growing cancer cases increases the US Helicobacter pylori non-invasive testing market growth.

Further, the growing geriatric population pool susceptible to gastric diseases will substantially increase the risk of H. pylori infection. Aging leads to thinning of the stomach lining, thus allowing the bacteria to pass through the protective lining, thereby increasing the disease prevalence among older people. Given the constant increase in the geriatric population base, the Washington Post has estimated that there will be nearly 80.8 million senior citizens in the US by 2040. Thus, growing geriatric population boosts the growth of US Helicobacter pylori non-invasive testing market.

According to a report from the National Institutes of Health, there was a 5% prevalence of H. pylori in children under the age of 10 in the US in 2020. In addition, the US Department of Health and Human Services reports that 30-40% of Americans are infected with H. pylori infection. Further, socioeconomic factors, such as low income, lack of education, household crowding, and immigration contribute to H. pylori infection among Hispanic and Black populations in the US. These statistics determine an increase in the need for non-invasive diagnostics for H. pylori in the US, thus, boosting the growth of the US Helicobacter pylori non-invasive testing market.

Test Type Insights

Based on test type, the US Helicobacter pylori non-invasive testing market is categorized into urea breath, stool antigen, and serology. In 2022, the urea breath segment held the largest share of the US Helicobacter pylori non-invasive testing market. Moreover, the same segment is expected to grow at the fastest rate during the coming years. A urea breath test (UBT) is one of the essential noninvasive methods for detecting H. pylori infection. The test involves detecting H. pylori based on its ability to produce urease enzyme, which results in the hydrolysis of orally administered urea into carbon dioxide and ammonia. These gases diffuse into the blood, and the lungs then excrete them. UBTs are reliable, low-burden tests validated in adults and children. Thus, these contribute to the growth of US Helicobacter pylori non-invasive testing market size.

According to Cancer Research UK, chronic bacterial infection causes long-lasting stomach inflammation, also known as severe chronic atrophic gastritis or SCAG; prolonged stomach ulcers can even lead to cancer. According to the World Health Organization (WHO), cancer is a significant cause of death across the world; approximately 1.9 million new cancer cases were recorded in the world in 2021. Colorectal cancer is a common type, with 146,589 new cases recorded in 2022. This type of cancer is more prevalent in middle-aged and geriatric populations. It rarely occurs among people aged less than 40 with genetic predisposition or predisposing conditions. The early detection of H. pylori via appropriate tests is necessary to prevent colorectal cancer. Early diagnosis is pivotal to reducing cancer-related mortality rates. Thus, the rising cases of bacterial infections are necessitating urea breath tests which contributes to the growth of US Helicobacter Pylori non-invasive testing market.

In February 2020, Gulf Coast Scientific received approval from the US Food and Drug Administration (FDA) for the Pylo Plus UBT System, a 13C UBT for the detection of H. pylori infection. In addition, key players in the US Helicobacter pylori non-invasive testing market form alliances to introduce new products and expand their presence. For instance, in 2021, Meridian Bio signed an agreement to acquire BreahTrek from Otsuka Pharmaceutical for US$ 20 million. Such collaborations led to the new product launches in the UBT segment and contribute the overall growth of US Helicobacter pylori non-invasive testing market during the forecast period.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the US H. pylori non-invasive testing market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the US H. pylori non-invasive testing market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 US Helicobacter pylori (H. pylori) Non-Invasive Testing Market - By Test Type
    • 1.3.2 US Helicobacter pylori (H. pylori) Non-Invasive Testing Market - By Test Method
    • 1.3.3 US Helicobacter pylori (H. pylori) Non-Invasive Testing Market - By End User

2. US Helicobacter pylori (H. pylori) Non-invasive Testing Market Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. US Helicobacter pylori (H. pylori) Non-invasive Testing Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 US PEST Analysis
  • 4.3 Experts Opinion
  • 4.4 United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Type - Volume 2022 (Million)

5. Helicobacter pylori (H. pylori ) Non-Invasive Testing Market - Key Industry Dynamics

  • 5.1 Key Market Drivers
    • 5.1.1 Increasing Prevalence of H. pylori Bacterial Infection
    • 5.1.2 Rising Market Development Activities in H. pylori Non-Invasive Testing
  • 5.2 Key Market Restraints
    • 5.2.1 Asymptomatic Nature of H. pylori
  • 5.3 Key Market Opportunities
    • 5.3.1 Increasing Use of Home-Based Point of Care Devices
  • 5.4 Future Trends
    • 5.4.1 Technological Advancements and Innovations in H. pylori Non-Invasive Testing
  • 5.5 Impact Analysis

6. US Helicobacter pylori (H. pylori) Non-Invasive Testing Market Analysis

  • 6.1 US Helicobacter pylori (H. pylori) Non-invasive Testing Market Revenue Forecast and Analysis
  • 6.2 Market Positioning of Key Players

7. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market Analysis - by Test Type

  • 7.1 Overview
  • 7.2 United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Type - Revenue and Forecast to 2028 (US$ Million)
  • 7.3 Urea Breath
    • 7.3.1 Overview
    • 7.3.2 Urea Breath: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Stool Antigen
    • 7.4.1 Overview
    • 7.4.2 Stool Antigen: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Serology
    • 7.5.1 Overview
    • 7.5.2 Serology: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)

8. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market Analysis - by Test Method

  • 8.1 Overview
  • 8.2 United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Method - Revenue and Forecast to 2028 (US$ Million)
  • 8.3 Laboratory Based
    • 8.3.1 Overview
    • 8.3.2 Laboratory Based: Helicobacter pylori (H. pylori) Non-Invasive Testing Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Point of Care
    • 8.4.1 Overview
    • 8.4.2 Point of Care: Helicobacter pylori (H. pylori) Non-Invasive Testing Market- Revenue and Forecast to 2028 (US$ Million)

9. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market Analysis - by End User

  • 9.1 Overview
  • 9.2 United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • 9.3 Hospitals
    • 9.3.1 Overview
    • 9.3.2 Hospitals: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.4 Reference Laboratories
    • 9.4.1 Overview
    • 9.4.2 Reference Laboratories: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Others
    • 9.5.1 Overview
    • 9.5.2 Others: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)

10. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market: Impact Assessment of COVID-19 Pandemic

  • 10.1 US: Impact Assessment of COVID-19 Pandemic

11. US Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Helicobacter pylori Non-Invasive Testing Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Bioneer Corp
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Meridian Bioscience Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Abbott Laboratories
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Thermo Fisher Scientific Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Bio-Rad Laboratories Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Coris BioConcept SPRL
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 DiaSorin SpA
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Sekisui Diagnostics LLC
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 CerTest Biotec SL
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 QuidelOrtho Corporation
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Type - Volume 2022 (Million)
  • Table 2. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Method - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. Recent Inorganic Growth Strategies in the H. pylori Non-Invasive Testing Market
  • Table 6. Recent Organic Growth Strategies in the H. pylori Non-Invasive Testing Market
  • Table 7. Glossary of Terms

List Of Figures

  • Figure 1. Helicobacter Pylori (H. pylori ) Non-Invasive Testing Market Segmentation
  • Figure 2. US Helicobacter pylori (H. pylori) Non-invasive Testing Market Overview
  • Figure 3. Urea Breath Segment Held Largest Share of Test Type Segment in Helicobacter pylori (H. pylori) Non-invasive Testing Market
  • Figure 4. US Helicobacter pylori (H. pylori) Non-invasive Testing Market, Industry Landscape
  • Figure 5. US: PEST Analysis
  • Figure 6. Experts Opinion
  • Figure 7. Helicobacter pylori Non-Invasive Testing Market Impact Analysis of Driver and Restraints
  • Figure 8. US Helicobacter pylori (H. pylori) Non-invasive Testing Market- Revenue Forecast and Analysis - 2020 - 2028
  • Figure 9. Market Positioning of Key Players in US Helicobacter pylori (H. pylori) Non-Invasive Testing Market
  • Figure 10. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Type, 2022 & 2028 (%)
  • Figure 11. Urea Breath: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 12. Stool Antigen: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 13. Serology: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 14. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Method, 2022 & 2028 (%)
  • Figure 15. Laboratory Based: Helicobacter pylori (H. pylori) Non-Invasive Testing Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 16. Point of Care: Helicobacter pylori (H. pylori) Non-Invasive Testing Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 17. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by End User, 2022 & 2028 (%)
  • Figure 18. Hospitals: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 19. Specialty Clinics: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 20. Others: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Impact of COVID-19 Pandemic on US Helicobacter pylori (H. pylori) Non-Invasive Testing Market
  • Figure 22. Growth Strategies in the Helicobacter pylori Non-Invasive Testing Market